Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

Trials to Evaluate the Safety, Tolerability and Preliminary Activity of Sensei’s SNS-301, in Combination with IMFINZI® (durvalumab), in Multiple Solid Tumor Types

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced a